Navigation Links
Trial combining anti-cancer drug and radiotherapy may lead to treatment for brain tumor
Date:9/30/2013

rative growth, making local therapies of very limited efficacy. The tumour is also resistant to all current chemotherapy treatments, and has devastating effects on the quality of life of patients. This brain tumour affects two to three people per 100,000, and is associated with a very poor prognosis, with an overall survival of 12 months.

"This is the first controlled trial of re-irradiation and the first performed in glioblastoma patients up to now. It was already known that APG101 might be an innovative approach for treating glioblastoma, but the size of the protein molecule was potentially too large to cross the protective bloodbrain barrier and target the tumour. Radiotherapy opens up this barrier and may therefore be an effective vehicle for this compound."

APG101 plays a major role in the blocking of the CD95/CD95L system. CD95 is a protein that acts as a receptor on the surface of cells. When this cell receptor binds with the CD95 ligand (CD95L) another protein it prompts the cell to die.

"Until 2008, it was thought that activating this system represented a potential strategy for treating glioblastoma," Prof Wick will explain. "But then it was realised that this made the cancer cells resistant to cell death and actually increased their ability to proliferate and spread to other tissues. Therefore, inhibition rather than activation is now considered a meaningful hypothesis to be tested, particularly in brain tumours."

The researchers found that patients with tumours expressing the CD95L protein had a worse prognosis than patients with tumours that did not express CD95L. However, CD95L-expressing tumours responded better to the APG101 combination treatment, with an overall survival of 11.5 months for these patients, compared to 8.2 months for patients without an active form of the protein.

"This also implies that CD95L would be one of the first predictive markers in neuro-oncology, which may help to define patie
'/>"/>

Contact: José Abad
ecco2013press@gmail.com
ECCO-the European CanCer Organisation
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
2. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
3. Canadian Journal of Cardiology publishes new atrial fibrillation guidelines
4. New clinical trial explores novel noninvasive colon cancer screening test
5. Clinical trial launches to see whether vitamin D helps treat multiple sclerosis
6. Trial seeks improved lung-cancer screening by combining imaging and biomarkers
7. Trial launched into curry chemicals cancer-fighting properties
8. Molecule found that inhibits estrogen, key risk factor for endometrial and breast cancers
9. VolitionRX Raises Over $1 Million To Begin Clinical Trials of Blood Based Diagnostic Tests
10. Delivery of gene-therapy for heart disease boosted 100-fold; now in 100-patient trial
11. Clinical trials for Alzheimers disease preventative drug to begin early 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2015)... , June 23, 2015   MedNet ... that supports the entire spectrum of clinical research, ... ™ , the company,s intuitive, flexible ... awarded a Silver 2015 Stevie® Award by the ... Products & Services Website category.  The American Business ...
(Date:6/23/2015)... June 23, 2015   Valencell, a ... results of a recent study that illustrates its ... wrist during activity. In a study conducted at ... along with the Apple Watch against a chest ... rate during activity. The study demonstrated that Valencell,s ...
(Date:6/18/2015)... 18, 2015 This report analyzes the worldwide ... following Product Segments, which includes Immunoassay Analyzers and Reagents: ... Radio Immunoassay Systems, and Nephelometric Immunoassay Systems. The report ... Canada , Japan , ... Latin America , and Rest of ...
Breaking Biology News(10 mins):MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29
... system defects, visual pathologies, heart disease. A tiny ... an excellent model system to unravel these diseases ... are currently working with this organism and producing ... Spain is among the leading countries for research ...
... by millions of balding men, artificially lowers the results ... test for prostate cancer, a multicenter study has found. ... age from 40 to 60 years old, is available ... is scheduled to be published after Jan. 1, 2007. ...
... have discovered that the Chlamydia bacterium, which causes a ... plants. That shared evolutionary heritage, which is not found ... for development of an effective cure for Chlamydia infections. ... plants had been proposed by others," said Thomas Leustek," ...
Cached Biology News:A valuable fly for research into disease 2Hair-growth drug artificially lowers PSA levels in prostate cancer screening, study finds 2Common ancestry of bacterium and plants could be key to an effective new treatment for chlamydia 2Common ancestry of bacterium and plants could be key to an effective new treatment for chlamydia 3
(Date:7/2/2015)... July 2, 2015  Spherix Incorporated (Nasdaq: SPEX ... and monetization of intellectual property, today announced a litigation ... Incorporated v. Verizon Services Corp. et al. , Case ... the Eastern District of Virginia , ... 2015 interpreting certain key claims in favor of the ...
(Date:7/1/2015)... RESEARCH TRIANGLE PARK, N.C. and ... -- Leading agricultural research firm AgBiome, and Genective, key ... partnership to accelerate the discovery of new generations ... new traits for insect control to counter the ... to partner with Genective, aligning AgBiome,s unique insect ...
(Date:7/1/2015)... 1, 2015  Axovant Sciences Ltd. (NYSE:  AXON), ... treatment of dementia, today announced that the company ... at 5:45 p.m. EDT following its presentation of ... Conference 2015 (AAIC). The event ... Dr. Lawrence Friedhoff , Chief Development Officer, ...
(Date:7/1/2015)... STRATFORD, CONNECTICUT (PRWEB) , ... July 01, 2015 ... ... disinfected or sterilized to combat pathogen transmission. CTI’ new Medical Joysticks have ... of medical devices now have an operator control device that will increase healthcare ...
Breaking Biology Technology:Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3AgBiome and Genective collaborate to create novel insect-resistant crops 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2
... SUNNYVALE, Calif., Sept. 26 Cepheid (Nasdaq:,CPHD) will ... Growth Stock,Conference on October 3, 2007 at 10:40 ... York. John R. Sluis, Cepheid,s Chief Financial Officer ... Officer, will provide,a corporate overview. The webcast, ...
... strategic platform for reducing risk of cancer ... drug development, ... ; MTAX) held its 2007 annual shareholders meeting,(Annual Meeting) on Tuesday, September ... a majority of CTI,s shares are,held by Italian shareholders. At the 2007 ...
... BioInformatics, SINGAPORE, Sept. 26 /Xinhua-PRNewswire/ -- ... Ltd, a leader in reconfigurable computing,applications headquartered ... The,BioIT Alliance is a cross-industry group working ... pace of drug discovery and realize the,potential ...
Cached Biology Technology:Cepheid to Present at William Blair Small-Cap Growth Stock Conference 2Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results 2Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results 3Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results 4Progeniq Joins Microsoft in Bio IT Alliance 2Progeniq Joins Microsoft in Bio IT Alliance 3
Cells are grown in triple flasks, roller bottles, or NUNC Factory. Viability and growth curves are generated from a parallel representative culture....
... Covance has generated hybridomas against a ... project initiation, you are provided with ... Hybridoma cell lines developed by Covance ... A typical hybridoma development project has ...
Standard and modified oligonucleotides up to 150 nt-long at any scale for broad applications. Price starts from 30p/base (10 nmole scale)....
... T7Select Packaging Extracts are optimized for maximum ... insert. The high efficiency extracts (> 109 ... to produce a library containing at least ... arms. The extracts are made from a ...
Biology Products: